MAYNE PHARMA, INC.
RALEIGH, NC

About Mayne Pharma Mayne Pharma Group Limited (Mayne Pharma) is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide. Mayne Pharma's roots can be traced to FH Faulding and Co, for many years one of the largest and most prominent public companies headquartered in South Australia. A technology driven company, Mayne Pharma has a significant product portfolio and pipeline, global reach through distribution partners in Australia, North America, Europe and Asia and two product development and manufacturing facilities based in Salisbury, Australia and Greenville, North Carolina, USA with expertise in formulating complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds. The business is supported by over 750 staff globally with more than 200 scientists employed. facility in Salisbury, South Australia is capable of developing products from formulation and clinical trial stages to validation and registration, right through to commercial scale manufacture of packaged goods. The Salisbury site: Includes an established manufacturing facility with capacity to produce 2.5 billion capsules and tablets, 100 ton of bulk product and 16 million units of liquid and cream product annually. Includes extensive product development laboratory space to accommodate all analytical processes and bench scale formulation through to pilot scale manufacturing and scale-up for multiple concurrent development projects. Is a center for product development activities, from formulation and clinical trial stage, to validation and registration, to commercial scale manufacture of packaged goods ready to be dispensed. facility in Greenville, North Carolina specializes in oral and topical dosage forms including highly potent compounds, Schedule II-V controlled substances, inherently unstable compounds and products with poor bioequivalence. The Greenville site: Is capable of handling potent and cytotoxic products and is DEA-approved for Schedule II-V controlled substances. Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that have been marketed around the world including: Metrics founded as a contract testing company in Greenville, North Carolina. Mayne Pharma acquires Metrics, Inc. - CDMO with niche generic product portfolio and pipeline. Mayne Pharma acquires Libertas, Inc. - US based generics business. Mayne Pharma launches Specialty Brands Sales Team to promote Doryx Mayne Pharma acquires US portfolio of products from Teva and Allergan in the US. Mayne Pharma acquires US foam dermatology products from GSK - Fabior From Faulding to Mayne Pharma The history of Mayne Pharma is intricate and began with FH Faulding & Co Ltd. From 1845 until 2001, Mayne Pharma was known as FH Faulding & Co where amongst other activities including pharmaceutical wholesaling and consumer health products, it built success around optimizing the delivery of oral dosage form drugs. In 2001, Mayne Group Ltd acquired FH Faulding & Co and then in November 2005, Mayne Group Ltd demerged the business into: Mayne Pharma Limited; a global pharmaceutical company focused on research and development, manufacture, marketing and distribution of injectable and oral pharmaceuticals; and Symbion Health Limited - a large Australian healthcare-focused company with leading market positions in pathology, diagnostic imaging, pharmacy and health-related consumer products. In February 2007, Hospira Inc announced that it had completed the acquisition of Mayne Pharma Limited as it tied in with the firm’s skills in specialty generic injectable pharmaceuticals. In October 2009, the oral pharmaceutical division of Mayne Pharma Limited was purchased from Hospira Inc by Halcygen Pharmaceuticals Ltd. In November 2010, Halcygen Pharmaceuticals Ltd changed its name to Mayne Pharma Group Limited, which is listed on the Australian Securities Exchange under the ASX code “MYX”. Mayne Pharma’s Board and leadership team is comprised of outstanding achievers in the global pharmaceutical industry, finance and business sectors. Mr. Corbett joined the Board of Mayne Pharma Group Limited in November 2010 and was appointed Chairman in January 2011. Mr. Corbett has been involved in the retail industry for more than 40 years. In 1984, Mr. Corbett joined the board of David Jones Australia as a Director of Operations and in 1990 was appointed to the board of Woolworths Limited and to the position of Managing Director of BigW. In 1999, Mr. Corbett was appointed Chief Executive Officer of Woolworths Limited, from which he retired in 2006. Mr. Corbett was Chairman of Fairfax Media Limited, one of Australia’s largest diversified media companies from October 2009 until 31 August 2015. Mr Corbett was a Director of the Reserve Bank of Australia until 1 December 2015, and was a director of Wal-Mart Stores until May 2016. He is Chair of Australian Leisure and Hospitality Group Pty Limited (ALH Group) and the Salvation Army Advisory Board. Mr. Richards has more than 27 years’ international experience in the pharmaceutical industry and has worked in Europe, the US and Asia. Prior to joining Mayne Pharma, Mr. Richards spent 10 years in Europe in a variety of leadership roles including President, Europe Middle East and Africa and President, Global Commercial Operations for Mayne Pharma Limited (acquired by Hospira in 2007). He also served on the Group Management Board of Actavis for 4 years where he was responsible for the firm’s global injectable/hospital business operations. Prior to working in Europe, Mr. Richards spent 14 years with FH Faulding and Co (acquired by Mayne Nickless in 2001) in a variety of roles including leading Faulding Pharmaceuticals Asia Pacific operations together with spending 5 years with Faulding in the US leading business development and portfolio management operations. Mr. Richards’ experience spans sales and marketing, regulatory/medical affairs, supply chain, business development, mergers and acquisitions, finance, intellectual property and manufacturing.